Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

plitidepsin

A cyclic depsipeptide isolated from the marine tunicate Aplidium albicans. Plitidepsin displays a broad spectrum of antitumor activities, inducing apoptosis by triggering mitochondrial cytochrome c release, initiating the Fas/DC95, JNK pathway and activating caspase 3 activation. This agent also inhibits elongation factor 1-a, thereby interfering with protein synthesis, and induces G1 arrest and G2 blockade, thereby inhibiting tumor cell growth.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	aplidine dehydrodemnin B dehydrodidemnin B
US brand name:	Aplidin
Abbreviation:	APLD DDB
Chemical structure:	N-[1-(1,2-dioxopropyl)-L-prolyl]didemnin A
NSC code:	638719

plitidepsin

Search NCI's Drug Dictionary